Efficacy And Safety Of Adding Sotagliflozin, A Dual SGLT1 And SGLT2 Inhibitor, To Optimized Insulin

Researchers conducted this post hoc analysis to test the safety and effectiveness of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index (BMI) ≥ 27 kg/m2. Sotagliflozin 200 and 400 mg added to insulin lowered HbA1c and increased time‐in‐range through continuous glucose monitoring vs placebo and also decreased body weight and systolic blood pressure. Consistent with published findings for the entire population, less severe hypoglycaemia and reported hypoglycaemia ≤ 3.1 mmol/L events and a higher incidence of diabetic ketoacidosis occurred with sotagliflozin vs placebo in patients with BMI ≥ 27 kg/m2. As an adjunct to optimized insulin therapy, sotagliflozin in overweight/obese patients with T1D addressed some unmet needs and may help achieve optimal glycemic control, reducing weight gain in this high‐risk population without raising the risk of hypoglycaemia.

​

Source